<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25673441</article-id><article-id pub-id-type="pmc">4836242</article-id><article-id pub-id-type="publisher-id">CMJ-128-433</article-id><article-id pub-id-type="doi">10.4103/0366-6999.151061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Shao-Chen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Lan-Hu</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Cheng-Cheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ming-Ting</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chi</surname><given-names>Jun-Ying</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nie</surname><given-names>Wen-Juan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumour Research Institute, Beijing 101149, China</aff><aff id="aff2"><label>2</label>Department of Patient Care Services, National Center for Tuberculosis Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Yu Lu, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, 97 Machang, Tongzhou District, Beijing 101149, China E-Mail: <email xlink:href="luyu4876@hotmail.com">luyu4876@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>2</month><year>2015</year></pub-date><volume>128</volume><issue>4</issue><fpage>433</fpage><lpage>437</lpage><history><date date-type="received"><day>11</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Chinese Medical Journal</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Decreases in the bioavailability of rifampicin (RFP) can lead to the development of drug resistance and treatment failure. Therefore, we investigated the relative bioavailability of RFP from one four-drug fixed-dose combination (FDC; formulation A) and three two-drug FDCs (formulations B, C, and D) used in China, compared with RFP in free combinations of these drugs (reference), in healthy volunteers.</p></sec><sec id="st2"><title>Methods:</title><p>Eighteen and twenty healthy Chinese male volunteers participated in two open-label, randomized two-period crossover (formulations A and C) or one three-period crossover (formulations B and D) study, respectively. The washout period between treatments was 7 days. Bioequivalence was assessed based on 90% confidence intervals, according to two one-sided <italic>t</italic>-tests. All analyses were done with DAS 3.1.5 (Mathematical Pharmacology Professional Committee of China, Shanghai, China).</p></sec><sec id="st3"><title>Results:</title><p>Mean pharmacokinetic parameter values of RFP obtained for formulations A, B, C, and D products were 11.42 &#x000b1; 3.41 &#x003bc;g/ml, 7.86 &#x000b1; 5.78 &#x003bc;g/ml, 13.05 &#x000b1; 6.80 &#x003bc;g/ml, and 16.18 &#x000b1; 3.87 &#x003bc;g/ml, respectively, for peak plasma concentration (C<sub>max</sub>), 91.43 &#x000b1; 30.82 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup>, 55.49 &#x000b1; 37.58 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup>, 96.50 &#x000b1; 47.24 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup>, 101.47 &#x000b1; 33.07 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup>, respectively, for area under the concentration-time curve (AUC<sub>0&#x02212;24 h</sub>).</p></sec><sec id="st4"><title>Conclusions:</title><p>Although the concentrations of RFP for formulations A, C, and D were within the reported acceptable therapeutic range, only formulation A was bioequivalent to the reference product. The three two-drug FDCs (formulations B, C and D) displayed inferior RFP bioavailability compared with the reference (Chinese Clinical Trials registration number: ChiCTR-TTRCC-12002451).</p></sec></abstract><kwd-group><kwd>Bioequivalence</kwd><kwd>Fixed-dose Combination</kwd><kwd>Rifampicin</kwd><kwd>Tuberculosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>Tuberculosis (TB) is still the infectious disease with the highest lethality, and China has the second highest TB burden globally.[<xref rid="ref1" ref-type="bibr">1</xref>] In 2013, there were notifications of 136,000 people with multidrug-resistant (MDR)-TB or rifampicin (RFP)-resistant TB (TB) who were eligible for MDR-TB treatment worldwide.[<xref rid="ref2" ref-type="bibr">2</xref>] The treatment of TB requires more than two drugs to prevent the emergence of resistant strains.[<xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Fixed-dose combinations (FDCs) are combinations of two or more drugs in a single pill. The first-line anti-TB drugs, including isoniazid (INH), RFP, pyrazinamide (PZA), and ethambutol (EMB) are often the components of FDCs. According to the published research, RFP is the questionable drug in such FDCs.[<xref rid="ref4" ref-type="bibr">4</xref>] RFP is lipophilic, whereas the other three drugs are hydrophilic. Studies have reported differences in RFP bioavailability between products containing RFP alone and FDC products.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p><p>The use of qualified FDC formulations in the treatment of TB can increase patients&#x02019; compliance compared with free combinations of the same drugs, and reduce the risk of treatment failure and emergence of drug-resistant strains. The WHO has thus recommended the use of FDCs in the treatment of TB and has published a list of prequalified products.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>]</p><p>The bioavailability of RFP is important in FDC. The aim of the present study was therefore to determine the bioequivalence of RFP in FDC formulations compared with RFP in free combinations in healthy Chinese male volunteers.</p></sec><sec sec-type="methods" id="sec1-2"><title>M<sc>ETHODS</sc></title><sec id="sec2-1"><title>Fixed-dose combination formulations and free combinations</title><p>Isoniazid tablets (100 mg, batch No. 1103021), EMB tablets (250 mg, batch No. 1103921), PZA tablets (250 mg, batch No. 1103031), and RFP capsules (150 mg, batch No. 1102041) were supplied by HongQi Pharmaceutical Company (Shenyang, China) as reference drugs. The four-drug FDC formulation was a tablet containing 75 mg INH, 150 mg RFP, 275 mg EMB, and 400 mg PZA (test formulation A, batch No. 1104022). The two-drug FDC test formulations were tablet B (150 mg INH, 300 mg RFP, batch No. 110204), capsule C (75 mg INH, 150 mg RFP, batch No. 110501) and capsule D (150 mg INH, 300 mg RFP, batch No. 110401). The FDC formulations were from different manufacturers except that formulation C and D were from the same manufacture.</p></sec><sec id="sec2-2"><title><italic>In vitro</italic> evaluation</title><p>The drug content and dissolution profiles of all formulations were determined in accordance with Chinese pharmacopeia protocols.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] The dissolution study was conducted at 75 r/min and 37&#x000b0;C using 900 ml phosphate buffer saline. Dissolved RFP was assayed at 254 nm using high-performance liquid chromatography (HPLC; Agilent 1200, USA).</p></sec><sec id="sec2-3"><title>Relative bioavailability study</title><p><bold>Experimental design</bold></p><p>Three bioavailability studies were conducted as open, two- or three-period, two- or three-sequence crossover trials. Two two-drug FDCs (B, D) containing INH and RFP were administered to a group of 18 volunteers with washout periods of 1 week between treatments. One two-drug FDC (C) containing INH and RFP was administered to a group of 20 volunteers with a washout period of 1 week. One four-drug FDC (A) containing INH, RFP, EMB, and PZA was administered to a group of 18 volunteers with a washout period of 1 week.</p><p>All volunteers underwent medical history screening, physical examination, blood pressure measurement, hemogram test, liver function test, hepatitis B virus test, chest radiography, electrocardiography, and routine urine analysis. Volunteers with a history of allergy to drugs related to the study medications or metabolic diseases, and those who had taken any drugs in the 2 weeks before the start of the study were excluded. The volunteers had no history of tobacco or alcohol use, or heart, liver, kidney or gastrointestinal disorders. The volunteers were aged between 20 and 40 years, and had a body mass index ranging from 19 to 24 kg/m<sup>2</sup>.</p><p>After overnight fasting, each volunteer received either a FDC formulation or the reference product (containing a single dose of 600 mg RFP) with 200 ml water [<xref ref-type="table" rid="T1">Table 1</xref>]. Volunteers received a light breakfast at 4 h postdose. Smoking and the consumption of alcohol were forbidden during the study. Blood samples (3 ml each) were collected in heparinized tubes at 0, 10, 20, and 40 min and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 h postdose. Serum was separated and stored at &#x02212;80&#x000b0;C until analysis.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Details of the bioequivalence trials of FDC formulations versus free combinations of Anti-TB drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" valign="top" colspan="1">FDC code</th><th align="left" rowspan="3" valign="top" colspan="1">FDC formulations</th><th align="center" colspan="4" rowspan="1">FDC dosage (mg)</th><th align="center" colspan="2" rowspan="1">Number of tablet/capsule</th><th align="center" rowspan="3" valign="top" colspan="1">Number of volunteers (<italic>n</italic>)</th><th align="center" rowspan="3" valign="top" colspan="1">Time (h)</th></tr><tr><th align="center" colspan="4" rowspan="1"><hr/></th><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">RFP</th><th align="center" rowspan="1" colspan="1">INH</th><th align="center" rowspan="1" colspan="1">PZA</th><th align="center" rowspan="1" colspan="1">EMB</th><th align="center" rowspan="1" colspan="1">FDC</th><th align="center" rowspan="1" colspan="1">Separate</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">Tablet/4 drug</td><td align="left" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">275</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Tablet/2 drug</td><td align="left" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">Capsule/2 drug</td><td align="left" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">Capsule/2 drug</td><td align="left" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">24</td></tr></tbody></table><table-wrap-foot><fn><p>FDC: Fixed-dose combination; TB: Tuberculosis; RFP: Rifampicin; INH: Isoniazid; PZA: Pyrazinamide; EMB: Ethambutol.</p></fn></table-wrap-foot></table-wrap><p><bold>Ethics</bold></p><p>The study was approved by the medical ethical committee of the Beijing Chest Hospital. All volunteers gave their informed consent prior to their inclusion in the study. Chinese Clinical Trials registration number: ChiCTR-TTRCC-12002451.</p></sec><sec id="sec2-4"><title>Assay method</title><p><bold>High-performance liquid chromatography-tandem mass spectrometry apparatus and conditions</bold></p><p>An Agilent HPLC Systems apparatus (Agilent Technologies, USA) equipped with a model G1329A ALS and a column heater (G1316A) was used. The mass spectrometer (MS) was a 6410B triple quadrupole MS (Agilent Technologies, USA). An electrospray ionization source was used.</p><p>The plasma concentration of RFP was measured using a HPLC-MS/MS method developed in our laboratory.[<xref rid="ref11" ref-type="bibr">11</xref>] Briefly, 100 &#x003bc;l of plasma sample was deproteinized with 200 &#x003bc;l of acetonitrile. The mixture was vortexed for 10 s and centrifuged for 10 min at 12,000 g; 2 &#x003bc;l of the supernatant was injected into the chromatographic system. Analysis was performed using a ZORBAX SB C-18 (2.1 mm &#x000d7; 50 mm, 1.8 &#x003bc;m; Agilent). The mobile phase was a mixture of water (0.1% formic acid): Acetonitrile (40:60 v/v). A flow rate of 0.3 ml/min was employed. The multiple reaction monitoring (MRM) transition was 823.2 &#x02192; 791.3 for RFP. Data were collected and processed using G3335AA-MASSHUNTER_ software-78 (Agilent Technologies, USA).</p><p>There was no interference with endogenous plasma compounds. The assay was linear over the range of 0.2&#x02013;28 &#x003bc;g/ml (<italic>r</italic><sup>2</sup> = 0.999). Coefficients of variation for intra- and inter-day precision were less than 5%. The limits of quantification and detection of RFP were 0.2 &#x003bc;g/ml and 0.01 &#x003bc;g/ml, respectively. RFP in blood samples remained stable at &#x02212;80&#x000b0;C over a period of 21 days.</p></sec><sec id="sec2-5"><title>Pharmacokinetic and statistical analysis</title><p>Pharmacokinetic (PK) parameters were analyzed by Drug and Statistics Software (DAS 3.1.5, Mathematical Pharmacology Professional Committee of China, Shanghai, China) using noncompartmental analysis. Peak plasma concentration (C<sub>max</sub>) and time to reach C<sub>max</sub> (T<sub>max</sub>) were directly obtained from individual plasma concentration-time profiles. The area under the concentration-time curve to the last measurable concentration (AUC<sub>0&#x02212;24 h</sub>) was calculated by the linear trapezoidal method. The half-life (t<sub>&#x000bd;</sub>) values were determined as 0.693/k.</p><p>Bioavailability equivalence was accepted if the 90% confidence intervals (90% CIs) calculated for the test/reference formulation mean ratios were within the ranges of 80%&#x02013;125% for AUC<sub>0&#x02212;24 h</sub> and 70%&#x02013;143% for C<sub>max</sub>. The T<sub>max</sub> between two treatment arms was analyzed using the Wilcoxon test, and differences were considered significant at <italic>P</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><sec id="sec2-6"><title><italic>In vitro</italic> evaluation</title><p>The dissolution profiles are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. For the reference, the percentage of RFP dissolved after 30 min was 84.9% &#x000b1; 1.32%, while for formulations A and C it was above 80% (96.2% &#x000b1; 0.50% and 97.2% &#x000b1; 1.64%, respectively), and for formulation B and D it was 33.7% &#x000b1; 0.48% and 65.8% &#x000b1; 1.05%. Formulation B and D did not meet the requirement of the dissolution test.[<xref rid="ref10" ref-type="bibr">10</xref>]</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Dissolution profiles of RFP from 4 FDCs (A, B, C, D) and free combination (Reference) in PBS solution. Dissolution profiles are presented as the mean of six tablets/capsule &#x000b1; SD. FDC: Fixed-dose combination; RFP: Rifampicin; SD: Standard deviation; PBS: Phosphate buffer saline.</p></caption><graphic xlink:href="CMJ-128-433-g001"/></fig></sec><sec id="sec2-7"><title>Relative bioavailability study</title><p>Mean concentration-time profiles of RFP for the four FDC formulations are presented in <xref ref-type="fig" rid="F2">Figure 2</xref>. The PK parameters (AUC<sub>0&#x02212;24 h</sub>, C<sub>max</sub>, T<sub>max</sub> and t<sub>&#x000bd;</sub>) of RFP are given in <xref ref-type="table" rid="T2">Table 2</xref>. The primary estimates of bioequivalence are shown in <xref ref-type="table" rid="T3">Table 3</xref>. All of these PK parameters were compared for both the FDCs and free combinations. Out of four FDC formulations tested, only one, FDC A, had comparable AUC<sub>0&#x02212;24 h</sub> and C<sub>max</sub> values of RFP to those for the corresponding free combinations and hence passed the bioequivalence test. For both the FDC and free combination, a 600-mg dose of RFP produced AUC<sub>0&#x02212;24 h</sub> values of 55.5&#x02013;108.3 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup> and C<sub>max</sub> values of 7.9&#x02013;16.2 &#x003bc;g/ml.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Mean concentration-time profiles of RFP after administration of free combination and FDCs in three bioequivalence trials (Formulation a&#x02013;d). Y-error bars indicate SD (for sample sizes refer to <xref ref-type="table" rid="T1">Table 1</xref>). FDC: Fixed-dose combination; RFP: Rifampicin; SD: Standard deviation.</p></caption><graphic xlink:href="CMJ-128-433-g002"/></fig><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Pharmacokinetic parameters of FDC formulations A, B, C and D for RFP resulted from different bioequivalence trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="3" valign="top" colspan="1">FDC code</th><th align="center" colspan="2" rowspan="1">AUC<sub>0&#x02013;24 h</sub> (&#x000b5;g&#x000b7;h<sup>&#x02212;1</sup>&#x000b7;ml<sup>&#x02212;1</sup>)</th><th align="center" colspan="2" rowspan="1">C<sub>max</sub> (&#x000b5;g/ml)</th><th align="center" colspan="2" rowspan="1">T<sub>max</sub> (h)</th><th align="center" colspan="2" rowspan="1"><italic>t</italic><sub>1/2</sub> (h)</th></tr><tr><th align="center" colspan="2" rowspan="1"><hr/></th><th align="center" colspan="2" rowspan="1"><hr/></th><th align="center" colspan="2" rowspan="1"><hr/></th><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">FDC</th><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">FDC</th><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">FDC</th><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">FDC</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">91.43 &#x000b1; 30.82</td><td align="center" rowspan="1" colspan="1">95.22 &#x000b1; 29.22</td><td align="center" rowspan="1" colspan="1">11.42 &#x000b1; 3.41</td><td align="center" rowspan="1" colspan="1">12.38 &#x000b1; 3.22</td><td align="center" rowspan="1" colspan="1">1.69 &#x000b1; 0.83</td><td align="center" rowspan="1" colspan="1">1.82 &#x000b1; 1.21</td><td align="center" rowspan="1" colspan="1">3.68 &#x000b1; 1.25</td><td align="center" rowspan="1" colspan="1">4.46 &#x000b1; 2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1">55.49 &#x000b1; 37.58</td><td align="center" rowspan="1" colspan="1">106.84 &#x000b1; 36.32</td><td align="center" rowspan="1" colspan="1">7.86 &#x000b1; 5.78</td><td align="center" rowspan="1" colspan="1">15.38 &#x000b1; 4.37</td><td align="center" rowspan="1" colspan="1">2.78 &#x000b1; 1.53</td><td align="center" rowspan="1" colspan="1">1.54 &#x000b1; 0.59</td><td align="center" rowspan="1" colspan="1">3.81 &#x000b1; 0.96</td><td align="center" rowspan="1" colspan="1">3.59 &#x000b1; 1.32</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">96.50 &#x000b1; 47.24</td><td align="center" rowspan="1" colspan="1">108.28 &#x000b1; 34.38</td><td align="center" rowspan="1" colspan="1">13.05 &#x000b1; 6.80</td><td align="center" rowspan="1" colspan="1">15.66 &#x000b1; 4.48</td><td align="center" rowspan="1" colspan="1">1.73 &#x000b1; 0.82</td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1; 0.57</td><td align="center" rowspan="1" colspan="1">3.31 &#x000b1; 1.52</td><td align="center" rowspan="1" colspan="1">3.38 &#x000b1; 1.77</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">101.47 &#x000b1; 33.07</td><td align="center" rowspan="1" colspan="1">106.84 &#x000b1; 36.32</td><td align="center" rowspan="1" colspan="1">16.18 &#x000b1; 3.87</td><td align="center" rowspan="1" colspan="1">15.38 &#x000b1; 4.37</td><td align="center" rowspan="1" colspan="1">1.68 &#x000b1; 0.65</td><td align="center" rowspan="1" colspan="1">1.54 &#x000b1; 0.59</td><td align="center" rowspan="1" colspan="1">3.66 &#x000b1; 1.28</td><td align="center" rowspan="1" colspan="1">3.59 &#x000b1; 1.32</td></tr></tbody></table><table-wrap-foot><fn><p>All the values are given as mean &#x000b1; SD. Sample size (n) is given in <xref ref-type="table" rid="T1">Table 1</xref>. FDC: Fixed-dose combination; AUC: Area under the curve; SD: Standard deviation; RFP: Rifampicin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Test/reference ratios and 90% CI derived from pharmacokinetic parameters of RFP for the assessment of bioequivalence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">FDC code</th><th align="left" rowspan="1" colspan="1">Pharmacokinetic parameters</th><th align="center" rowspan="1" colspan="1">Test/reference (%)</th><th align="center" rowspan="1" colspan="1">90% CI</th><th align="left" rowspan="1" colspan="1">Bioequivalence result</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">AUC<sub>0-24 h</sub></td><td align="center" rowspan="1" colspan="1">94.7</td><td align="center" rowspan="1" colspan="1">89.5&#x02013;100.2</td><td align="left" rowspan="1" colspan="1">Passed</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" rowspan="1" colspan="1">90.9</td><td align="center" rowspan="1" colspan="1">81.8&#x02013;100.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">AUC<sub>0-24 h</sub></td><td align="center" rowspan="1" colspan="1">44.4</td><td align="center" rowspan="1" colspan="1">36.7&#x02013;53.8</td><td align="left" rowspan="1" colspan="1">Failed</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" rowspan="1" colspan="1">41.8</td><td align="center" rowspan="1" colspan="1">33.6&#x02013;51.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">AUC<sub>0-24 h</sub></td><td align="center" rowspan="1" colspan="1">84.0</td><td align="center" rowspan="1" colspan="1">76.9&#x02013;91.7</td><td align="left" rowspan="1" colspan="1">Failed</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" rowspan="1" colspan="1">76.9</td><td align="center" rowspan="1" colspan="1">67.5&#x02013;87.6</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">AUC<sub>0-24 h</sub></td><td align="center" rowspan="1" colspan="1">95.7</td><td align="center" rowspan="1" colspan="1">79.0&#x02013;115.9</td><td align="left" rowspan="1" colspan="1">Failed</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C<sub>max</sub></td><td align="center" rowspan="1" colspan="1">106.1</td><td align="center" rowspan="1" colspan="1">85.3&#x02013;131.8</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Statistical evaluation was done by DAS 3.1.5. 90% CI of bioequivalence for AUC<sub>0&#x02013;24 h</sub> is 80&#x02013;125%, for C<sub>max</sub> is 70&#x02013;143%. FDC: Fixed-dose combination; CI: Confidence interval; AUC: Area under the curve; RFP: Rifampicin.</p></fn></table-wrap-foot></table-wrap><p>The concentration of RFP in FDC formulation B was considerably lower compared with the free combination, at approximately 50% throughout the full sampling time interval of the reference. The 90% CIs for the C<sub>max</sub> and AUC<sub>0&#x02212;24 h</sub> ratios were clearly outside the 70%&#x02013;143% and 80%&#x02013;125% ranges for the free combination, indicating the bioinequivalence of formulation B compared with the reference product.</p><p>The differences between the C<sub>max</sub> of the FDC and free combination were not apparent for formulations C and D, shown in <xref ref-type="fig" rid="F2">Figure 2</xref>. However, <xref ref-type="table" rid="T3">Table 3</xref> shows that formulations C and D were not equivalent to the reference formulations. About 90% CI of AUC<sub>0&#x02212;24 h</sub> (76.9%&#x02013;91.7%) and C<sub>max</sub> (67.5%&#x02013;87.6%) in formulation C were both inequivalent compared with a reference. Of the 20 volunteers, 10 had AUC<sub>0&#x02212;24 h</sub> values that were less than 80% of the reference and seven had C<sub>max</sub> values that were &#x0003c;70% of the reference. The AUC<sub>0&#x02212;24 h</sub> of formulation D was within the range of 79&#x02013;116% of the reference. Seven volunteers had AUC<sub>0&#x02212;24 h</sub> values that were less than 80% of the reference in formulation D (40.85, 58.49, 63.00, 76.94, 81.18, 81.63, and 84.78 &#x003bc;g&#x000b7;h<sup>&#x02212;1</sup> &#x000b7;ml<sup>&#x02212;1</sup>, respectively). The C<sub>max</sub> of formulation D passed the bioequivalence test (85.3&#x02013;131.8%).</p><p>The t<sub>&#x000bd;</sub> of the reference product (3.38&#x02013;4.46 h) and test formulations (3.31&#x02013;3.81 h) were within the interval reported by other authors.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p><p>The T<sub>max</sub> for the test product was not significantly different from that of the reference product except for formulation B, for which the T<sub>max</sub> was 2.78 &#x000b1; 1.53 h (<italic>P</italic> &#x0003c; 0.05) while the reference was 1.54 &#x000b1; 0.59 h.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>D<sc>ISCUSSION</sc></title><p>Resistance to INH and RFP often results in incurable TB. The global spread of TB is further complicated by the ubiquitous appearance of MDR strains defined as those, which are resistant to at least INH and RFP.[<xref rid="ref14" ref-type="bibr">14</xref>] The effective treatment of TB requires high-quality drug products. The WHO has suggested that qualified FDCs be used for the treatment of TB.[<xref rid="ref15" ref-type="bibr">15</xref>] A clinical trial conducted at11 sites in 9 countries supported the WHO recommendations for the use of FDCs because of the potential advantages compared with free combinations of the component drugs.[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>Fewer previous studies have been conducted in China comparing the bioequivalence of the anti-TBFDC products available there.[<xref rid="ref11" ref-type="bibr">11</xref>] Because there was no certified reference FDC product available in China at the time of this study, we used separate drugs as the reference in this bioequivalence study.</p><p>Agrawal <italic>et al</italic>. suggested that the RFP bioavailability problem is more attributable to extrinsic factors such as formulation or RFP bulk material rather than intrinsic variability of RFP absorption.[<xref rid="ref17" ref-type="bibr">17</xref>] Our <italic>in vitro</italic> dissolution test showed that, although formulation C meets the dissolution requirement, it failed the bioequivalence study. The test showed that, even when RFP formulations meet dissolution requirements, the drug is not always well absorbed. Other authors have also found that the relationship between RFP dissolution properties and bioavailability is poor.[<xref rid="ref18" ref-type="bibr">18</xref>]</p><p>We chose sample sizes of 18&#x02013;20 volunteers and a sampling time of 24 h for our study because previous studies have shown these to be sufficient to demonstrate bioinequivalence.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] In the relative bioavailability study, the RFP concentration-time profile of formulation B clearly differed from the reference, while those of the other three FDCs were similar to the reference [<xref ref-type="fig" rid="F2">Figure 2</xref>]. The C<sub>max</sub> and AUC<sub>0&#x02212;24 h</sub> of formulations A, C, and D also had no obvious difference from the reference. The RFP C<sub>max</sub> value of formulations A, C, and D were above the minimum therapeutic plasma concentration (10 &#x003bc;g/ml), and this was comparable to the results from an Indian study, which used a dose of 600 mg.[<xref rid="ref21" ref-type="bibr">21</xref>]</p><p>We examined the data of each volunteer and found substantial inter-subject variability in the data. For formulation C, half of the volunteers&#x02019; AUC<sub>0&#x02212;24 h</sub> values were below the 80% mean value of the reference and one-third of the volunteers&#x02019; C<sub>max</sub> values were below the 70% mean value of the reference. The other volunteers had higher values of the AUC<sub>0&#x02212;24 h</sub> and C<sub>max</sub>, indicating that the data were polarized. The situation was similar for formulation D, but only the AUC<sub>0&#x02212;24 h</sub> was slightly lower than 80% value of the reference. Based on this consideration, although sample sizes of 18 volunteers are typical for bioequivalence studies, a small sample from a single center was a limitation of this study. Furthermore, healthy male volunteers are not representative of patient populations.</p><p>Out of four FDC formulations evaluated, only one formulation was bioequivalent for RFP to free combinations of the component drugs, whereas the other three formulations were below the limits of bioequivalence. Our studies showed the importance of conducting bioequivalence studies before the distribution of FDC products within the Chinese health system.</p><p>Any reduction in the bioavailability of anti-TB drugs such as RFP could have serious consequences, including potential treatment failure and selection of drug-resistant mutants. The poor bioavailability of RFP represents a serious problem for the success of TB treatment, which must be addressed by the Chinese health authorities.</p></sec></body><back><ack><title>A<sc>CKNOWLEDGMENTS</sc></title><p>The authors thank all the participants in the trial and are grateful to Wei-Jie Zhao and Su-Hua Zheng in Beijing Tuberculosis and Thoracic Tumor Research Institute for their help in data analysis.</p></ack><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Li-Min Chen</p></fn><fn fn-type="supported-by"><p><bold>Source of Support:</bold>This study was supported by a grant from The National S and T Major Special Project on Major New Drug Innovation (No. 2010ZX09102-301).</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="book"><article-title>Ministry of Health of the People's Republic of China. The National Tuberculosis Drug-Resistance Baseline Survey Report (2007&#x02013;2008)</article-title><year>2010</year><publisher-loc>Beijing</publisher-loc><publisher-name>People's Medical Publishing House</publisher-name></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><article-title>World Health Organization. Global Tuberculosis Report 2014</article-title><year>2014</year><date-in-citation>Accessed December, 2014</date-in-citation><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>WHO</publisher-name><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1">http://www.apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1</uri></comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blomberg</surname><given-names>B</given-names></name><name><surname>Spinaci</surname><given-names>S</given-names></name><name><surname>Fourie</surname><given-names>B</given-names></name><name><surname>Laing</surname><given-names>R</given-names></name></person-group><article-title>The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis</article-title><source>Bull World Health Organ</source><year>2001</year><volume>79</volume><fpage>61</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11217670</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mil&#x000e1;n-Segovia</surname><given-names>RC</given-names></name><name><surname>Dom&#x000ed;nguez-Ram&#x000ed;rez</surname><given-names>AM</given-names></name><name><surname>Jung-Cook</surname><given-names>H</given-names></name><name><surname>Maga&#x000f1;a-Aquino</surname><given-names>M</given-names></name><name><surname>Romero-M&#x000e9;ndez</surname><given-names>MC</given-names></name><name><surname>Medell&#x000ed;n-Garibay</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation</article-title><source>Int J Tuberc Lung Dis</source><year>2010</year><volume>14</volume><fpage>1454</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20937187</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panchagnula</surname><given-names>R</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name></person-group><article-title>Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin</article-title><source>Int J Pharm</source><year>2004</year><volume>271</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15129967</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>G</given-names></name><name><surname>Fourie</surname><given-names>PB</given-names></name><name><surname>Padayatchi</surname><given-names>N</given-names></name><name><surname>Onyebujoh</surname><given-names>PC</given-names></name><name><surname>McIlleron</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market</article-title><source>Int J Tuberc Lung Dis</source><year>1999</year><volume>3</volume><fpage>S309</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">10593710</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><article-title>International Union Against Tuberculosis and Lung Disease/World Health Organization. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union against Tuberculosis and Lung Disease and the tuberculosis programme of the World Health Organization</article-title><source>Tuber Lung Dis</source><year>1994</year><volume>75</volume><fpage>180</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">7919308</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchison</surname><given-names>DA</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins</article-title><source>Int J Tuberc Lung Dis</source><year>2012</year><volume>16</volume><fpage>1186</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22794180</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="book"><article-title>National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 2</article-title><year>2010</year><publisher-loc>Beijing</publisher-loc><publisher-name>China Medical Science Press, Appendix XC</publisher-name><fpage>85</fpage><lpage>6</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><article-title>National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 2. (In Chinese)</article-title><year>2010</year><publisher-loc>Beijing</publisher-loc><publisher-name>China Medical Science Press</publisher-name><fpage>297</fpage><lpage>9</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers</article-title><source>Clin Ther</source><year>2013</year><volume>35</volume><fpage>161</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23410999</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Alisjahbana</surname><given-names>B</given-names></name><name><surname>de Lange</surname><given-names>WC</given-names></name><name><surname>Borst</surname><given-names>F</given-names></name><name><surname>Danusantoso</surname><given-names>H</given-names></name><name><surname>van der Meer</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia</article-title><source>Int J Tuberc Lung Dis</source><year>2002</year><volume>6</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">12068982</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padgaonkar</surname><given-names>KA</given-names></name><name><surname>Revankar</surname><given-names>SN</given-names></name><name><surname>Bhatt</surname><given-names>AD</given-names></name><name><surname>Vaz</surname><given-names>JA</given-names></name><name><surname>Desai</surname><given-names>ND</given-names></name><name><surname>D&#x02019;Sa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers</article-title><source>Int J Tuberc Lung Dis</source><year>1999</year><volume>3</volume><fpage>627</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10423226</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>XC</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Xie</surname><given-names>XL</given-names></name><name><surname>Xu</surname><given-names>YC</given-names></name><name><surname>Zhao</surname><given-names>ZX</given-names></name></person-group><article-title>Gene chip array for differentiation of mycobacterial species and detection of drug resistance</article-title><source>Chin Med J</source><year>2012</year><volume>125</volume><fpage>3292</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22964326</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="book"><article-title>World Health Organization. Treatment of Tuberculosis: Guidelines</article-title><year>2010</year><date-in-citation>Accessed December, 2014</date-in-citation><edition>4th ed</edition><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>WHO</publisher-name><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.who.int/tb/publications/2010/9789241547833/en">http://www.who.int/tb/publications/2010/9789241547833/en</uri></comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lienhardt</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>SV</given-names></name><name><surname>Burgos</surname><given-names>M</given-names></name><name><surname>Yorke-Edwards</surname><given-names>V</given-names></name><name><surname>Rigouts</surname><given-names>L</given-names></name><name><surname>Anyo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: The study C randomized controlled trial</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>1415</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">21486974</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Kaur</surname><given-names>KJ</given-names></name><name><surname>Bhade</surname><given-names>S</given-names></name><name><surname>Kaul</surname><given-names>CL</given-names></name><name><surname>Panchagnula</surname><given-names>R</given-names></name></person-group><article-title>Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin</article-title><source>Pharmacol Res</source><year>2004</year><volume>50</volume><fpage>317</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15225676</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashokraj</surname><given-names>Y</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Varma</surname><given-names>MV</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Gunjan</surname><given-names>K</given-names></name><name><surname>Kaur</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: An <italic>in vitro</italic> study</article-title><source>Int J Tuberc Lung Dis</source><year>2004</year><volume>8</volume><fpage>1081</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15455592</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>KJ</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Bhade</surname><given-names>S</given-names></name><name><surname>Kaul</surname><given-names>CL</given-names></name><name><surname>Panchagnula</surname><given-names>R</given-names></name></person-group><article-title>Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations</article-title><source>Int J Tuberc Lung Dis</source><year>2005</year><volume>9</volume><fpage>1273</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16333937</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>KJ</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Bhade</surname><given-names>SR</given-names></name><name><surname>Kaul</surname><given-names>CL</given-names></name><name><surname>Panchagnula</surname><given-names>R</given-names></name></person-group><article-title>Determination of rifampicin bioequivalence in a three-drug FDC by WHO and Indian protocols: Effect of sampling schedule and size</article-title><source>Int J Tuberc Lung Dis</source><year>2005</year><volume>9</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15675554</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Kaur</surname><given-names>KJ</given-names></name><name><surname>Bhade</surname><given-names>SR</given-names></name><name><surname>Kaul</surname><given-names>CL</given-names></name><name><surname>Panchagnula</surname><given-names>R</given-names></name></person-group><article-title>Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels</article-title><source>Int J Pharm</source><year>2004</year><volume>276</volume><fpage>41</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15113612</pub-id></element-citation></ref></ref-list></back></article>